You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Novo Nordisk stock crashed 17% on Friday after revealing disappointing trial results.
In this video, I will cover the recent updates regarding Novo Nordisk (NVO -2.49%) and whether or not the dip is worth buying over Eli Lilly (LLY -3.41%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
*Stock prices used were from the trading day of Dec. 20, 2024. The video was published on Dec. 22, 2024.
Neil Rozenbaum has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Neil is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
Stocks Mentioned
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
